Trial · NCT01242813
Results by group143
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 143
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Complete or Almost Complete Response at Day 15 | Canakinumab | 95 | 95% Confidence Interval 75.1 to 99.9 | Percentage of participants | |
| Percentage of Participants With Complete or Almost Complete Response at Day 8 | Canakinumab | 80 | 95% Confidence Interval 56.3 to 94.3 | Percentage of participants | |
| Percentage of Participants With Complete Clinical Remission at Day 8 and 15 | Canakinumab | Day 8 | 90 | 95% Confidence Interval 68.3 to 98.8 | Percentage of participants |
| Percentage of Participants With Complete Clinical Remission at Day 8 and 15 | Canakinumab | Day 15 | 100 | 95% Confidence Interval 83.2 to 100 | Percentage of participants |
| Percentage of Participant With Target Levels of C-reactive Protein (CRP) and Serum Amyloid A Protein (SAA) at Day 8 and 15 | Canakinumab | Day 8 | 35 | 95% Confidence Interval 15.4 to 59.2 | Percentage of participants |
| Percentage of Participant With Target Levels of C-reactive Protein (CRP) and Serum Amyloid A Protein (SAA) at Day 8 and 15 | Canakinumab | Day 15 | 60 | 95% Confidence Interval 36.1 to 80.9 | Percentage of participants |
| Time to Physician's Assessed Clinical Remission | Canakinumab | 4 | 95% Confidence Interval 3 to 8 | Days | |
| Percentage of Participants With Complete or Almost Complete Response at Day 15 After Receiving Additional Dose at Day 8 | Canakinumab | 100 | 95% Confidence Interval 39.8 to 100 | Percentage of participants | |
| Time to Participant's Assessed Clinical Remission | Canakinumab | 3 | 95% Confidence Interval 1 to 11 | Days | |
| Percentage Change From Baseline in C-reactive Protein (CRP) and Serum Amyloid A (SAA) Concentration to End of Study | Canakinumab | CRP | -92.19 | Full Range -99 to 43.6 | Percent change |
| Percentage Change From Baseline in C-reactive Protein (CRP) and Serum Amyloid A (SAA) Concentration to End of Study | Canakinumab | SAA | -96.54 | Full Range -99.8 to 68.3 | Percent change |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Skin rash absent | 95 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Skin rash minimal | 5 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Skin rash mild | 0 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Skin rash moderate | 0 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Skin rash severe | 0 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Eye manifestations absent | 90 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Eye manifestations minimal | 10 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Eye manifestations mild | 0 | Percentage of participants | |
| Percentage of Participants With Defined Grades for Skin Rash, Eye Manifestations, Extremity Pain and Abdominal Pain | Canakinumab | Eye manifestations moderate | 0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01242813/results